联合吸入噻托溴铵与沙美特罗/丙酸氟替卡松治疗重度COPD患者缓解期疗效的观察 |
| |
引用本文: | 梁建中,尹辉明,周康仕,周宏花. 联合吸入噻托溴铵与沙美特罗/丙酸氟替卡松治疗重度COPD患者缓解期疗效的观察[J]. 医学临床研究, 2010, 27(6): 1059-1061 |
| |
作者姓名: | 梁建中 尹辉明 周康仕 周宏花 |
| |
作者单位: | 怀化医学高等专科学校附属怀化市第三人民医院呼吸科,湖南,怀化,418000 |
| |
摘 要: | 【目的】观察联合吸入噻托溴铵与沙美特罗/替卡松粉吸入剂治疗重度慢性阻塞性肺疾病(COPD)缓解期的疗效。【方法】重度COPD患者68例,随机分为治疗组和对照组。在常规治疗的基础上,对照组给予吸入沙美特罗/替卡松粉(salmeterol/fluticason,SFC)吸入剂(50μg/500μg),2次/日,治疗组在此基础上联合噻托溴铵吸入刺(18μg),1次/日,坚持治疗与观察1年,每3个月进行圣乔治呼吸问卷(SGRQ)调查评分、6分钟步行距离试验(6MD),肺功能测定(FEV1、FEV1占预计值%)及详细观察并记录急性加重的住院次数及药物不良反应。【结果】两组治疗6、9、12个月后SGRQ总分减少、6MD距离增加,且较治疗前差异有显著性(P〈o.05);治疗组9、12个月后sGRQ总分的减少、6MD距离的增加与对照组相比,差异有显著性(P〈0.05),两组治疗9、12个月后FEV1值、FEV1占预计值%均较治疗前差异有显著性(P〈0.05),但两组之间差异无显著性(P〉0.05);治疗组急性加重住院次数为显著少于对照组(P〈0.05),两组均无明显副作用。【结论】联合噻托溴与沙美特罗/丙酸氟替卡松治疗重度COPD较单纯吸入沙美特罗/丙酸氟替卡松效果好,使用安全,值得临床推广。
|
关 键 词: | 肺疾病 阻塞性/药物疗法 肾上腺素能口激动剂/投药和剂量 消炎药 甾类/投药和剂量 |
Effect of Tiotropium Combined with Seretide for the Treatment of Chronic Obstructive Pulmonary Disease Patients in Remission Period |
| |
Affiliation: | LIANG Jian-zhong, YIN Hui-ming, ZHOU Kang-shi,et al (Department of Respiratory Disease, Third Hospital of Huaihua City,Affiliated to Huaihua Medical College, Hunan 418000, China ) |
| |
Abstract: | [Objective]To observe the effect of tiotropium combined with seretide(salmeterol/ fluticasone propionate powder inhalant) for the treatment of severe chronic obstructive pulmonary disease(COPD) in re mission period. [Methods] Sixty eight patients with severe COPD were randomly divided into treatment group and control group. The control group was given seretide(50μg/500μg) twice a day, while the treatment group was given seretide(50μg/500μg) combined with tiotropium inhalant once a day. St. George rating question- naire(SGRQ), 6-minute walking distance test (6MD) and lung function test (FEV1 and FEV1%) were observed, and the time of hospitalization and adverse reactions were recorded. [Results]Compared with before treatment, the total scores of SGRQ decreased and 6MD increased in two groups at 6-, 9- and 12-month after treatment, and there was significant difference( P 〈0.05). There were significant differences in the decrease of SGRQ scores and the increase of 6MD between the treatment group and control group( P 〈0.05). And there was significant difference in FEV1 and FEVI1% in two groups between 9- and 12 month after treatment and before treatment( P 〈0. 05), but there was no significant difference between two groups( P 〉0. 05). The time of hospitalization due to acute exacerbation in the treatment group was significantly less than that in the control group( P 〈0.05). No obvious complication in both groups was found. [Conclusion] Tiotropium combined with seretide in the treatment of severe COPD in remission period is more effective than only seretide inhalation. It is safe and worthy of being extended in clinics. |
| |
Keywords: | lung diseases, obstructive/DT adrenergic beta-angonists/AD anti-inflammatory agents, steroidal/AD |
本文献已被 维普 万方数据 等数据库收录! |
|